Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?

Cancer - 15 Feb 2010

Noon Aidan P, Vlatković Nikolina, Polański Radosław, Maguire Maria, Shawki Howida, Parsons Keith, Boyd Mark T

Abstract excerpt

Renal cell carcinoma (RCC) is the most common type of kidney cancer and follows an unpredictable disease course. To improve prognostication, a better understanding of critical genes associated with disease progression is required. The objective of this review was to focus attention on 2 such genes, p53 and murine double minute 2 (MDM2), and to provide a comprehensive summary and critical analysis of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Disease Progression

Share to Genes, p53

Share to Kidney Neoplasms

Share to Proto-Oncogene Proteins c-mdm2

Share to Tumor Suppressor Protein p53

Share to Up-Regulation

Source

Open in PubMed Open full text

Identifiers

PMID: 20052733
DOI: 10.1002/cncr.24841
PMCID: PMC3536467

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?PMID 20052733Read ↗

Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.Semantic proximity Read ↗

Targeting miRNAs in renal cell carcinoma: emerging therapeutic strategiesSemantic proximity Read ↗

From bench to bedside: current and future applications of molecular profiling in renal cell carcinomaSemantic proximity Read ↗

Kidney cancer: identification of novel targets for therapy.Semantic proximity Read ↗

p53 Regulation and Function in Renal Cell CarcinomaSemantic proximity Read ↗

The T309G murine double minute 2 gene polymorphism is an independent prognostic factor for patients with renal cell carcinoma.Semantic proximity Read ↗

Developing novel therapeutic strategies for targeting the p53 pathway in renal cell carcinomaSemantic proximity Read ↗

The Underestimated Role of the p53 Pathway in Renal CancerSemantic proximity Read ↗

P53 mutations and other prognostic factors of renal cell carcinoma.Semantic proximity Read ↗

p53 mutations and MDM-2 amplification in renal cell cancers.Semantic proximity Read ↗

Selected immunohistochemical features of conventional renal cell carcinomas coexpressing P53 and MDM2.Semantic proximity Read ↗

MDM2-p53 pathway in hepatocellular carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.